Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Inclusion Criteria

• •Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
• •Migraine attacks, on average, lasting about 4 - 72 hours if untreated.
• •4 to 14 migraine days per month on average across the 3 months prior to the Screening Visit (month is defined as 28 days for the purpose of this protocol).
• •Less than 15 headache days (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase.
• •Subjects must be able to distinguish migraine attacks from tension/cluster headaches.
• •Subjects on prophylactic migraine medication (excluding CGRP antagonists) are permitted to remain on therapy if they have been on a stable dose for at least 3 months (12 weeks) prior to the Screening Visit, and if the dose is not expected to change during the course of the study.
• •Triptan unsuitable